Literature DB >> 3280184

Measles virus infection of unstimulated blood mononuclear cells in vitro: antigen expression and virus production preferentially in monocytes.

R Salonen1, J Ilonen, A Salmi.   

Abstract

Synthesis of measles virus antigens occurred only in a small percentage of peripheral blood mononuclear cells infected in vitro with measles virus without mitogenic stimulation. The infection cycle was restricted as only low amounts of infectious virus were released but all the major structural viral proteins were present as shown by immunofluorescence with monoclonal antibodies. Cells with viral antigen synthesis were characterized by double labelling and by infecting selectively depleted subpopulations. In 3-day cultures, up to 80% of the cells with measles virus antigen were shown to be monocytes by specific staining with anti-MMA and anti-Leu M3 monoclonal antibodies and up to 40% of the monocytes were infected. Less than 10% of the cells expressing virus antigens carried the lymphocyte marker OKT3, the majority of these cells belonging to the Leu3a (helper) population. Anti-alpha-interferon treatment increased the number of measles-positive cells and the release of infectious virus in preparations enriched for monocytes, but had no significant effect on infection of lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280184      PMCID: PMC1541436     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Abortive and productive infections of human mononuclear phagocytes by type I herpes simplex virus.

Authors:  C A Daniels; E S Kleinerman; R Snyderman
Journal:  Am J Pathol       Date:  1978-04       Impact factor: 4.307

2.  Virus-lymphocyte interactions: infection of Tg and Tm subsets by measles virus.

Authors:  J R Huddlestone; P W Lampert; M B Oldstone
Journal:  Clin Immunol Immunopathol       Date:  1980-03

3.  Replication and persistence of measles virus in defined subpopulations of human leukocytes.

Authors:  B S Joseph; P W Lampert; M B Oldstone
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

4.  Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.

Authors:  G Köhler; C Milstein
Journal:  Eur J Immunol       Date:  1976-07       Impact factor: 5.532

5.  Measles virus persistence in human lymphocytes: a role for virus-induced interferon.

Authors:  S Jacobson; H F McFarland
Journal:  J Gen Virol       Date:  1982-12       Impact factor: 3.891

6.  Different effects of influenza virus, respiratory syncytial virus, and Sendai virus on human lymphocytes and macrophages.

Authors:  N J Roberts
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

7.  Activation of measles virus from silently infected human lymphocytes.

Authors:  C J Lucas; J C Ubels-Postma; A Rezee; J M Galama
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

8.  Growth of measles virus in a human macrophagelike cell line: U937.

Authors:  M W Brandriss; J J Schlesinger; S E Chapman
Journal:  Am J Pathol       Date:  1982-11       Impact factor: 4.307

9.  Studies on leukocyte cultures in measles. II. Detection of measles virus antigen in human leucocytes by immunofluorescence.

Authors:  B O Osunkoya; G I Adeleye; T A Adejumo; L S Salimonu
Journal:  Arch Gesamte Virusforsch       Date:  1974

10.  Viruses disrupt functions of human lymphocytes. II. Measles virus suppresses antibody production by acting on B lymphocytes.

Authors:  M B McChesney; R S Fujinami; P W Lampert; M B Oldstone
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals.

Authors:  Sallie R Permar; Diane E Griffin; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2006-04

2.  Infection of human peripheral blood mononuclear cells with a temperature-sensitive mutant of measles virus.

Authors:  S Vydelingum; J Ilonen; R Salonen; R Marusyk; A Salmi
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Measles virus inhibits lymphocyte proliferation in vitro by two different mechanisms.

Authors:  R Salonen; J Ilonen; A A Salmi
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

4.  Induction of CD4 T cell proliferation and in vitro Th1-like cytokine responses to measles virus.

Authors:  R C Howe; N Dhiman; I G Ovsyannikova; G A Poland
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

5.  Cloning of human T cells specific for measles virus haemagglutinin and nucleocapsid.

Authors:  J Ilonen; M J Mäkelä; B Ziola; A A Salmi
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

6.  Relative ability of different bovine leukocyte populations to support active replication of rinderpest virus.

Authors:  J E Rey Nores; K C McCullough
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Edmonston measles virus prevents increased cell surface expression of peptide-loaded major histocompatibility complex class II proteins in human peripheral monocytes.

Authors:  Mamadi Yilla; Carole Hickman; Marcia McGrew; Elizabeth Meade; William J Bellini
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Measles virus-induced changes in leukocyte function antigen 1 expression and leukocyte aggregation: possible role in measles virus pathogenesis.

Authors:  N Attibele; P R Wyde; J Trial; S C Smole; C W Smith; R D Rossen
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Efficiency of measles virus entry and dissemination through different receptors.

Authors:  Urs Schneider; Veronika von Messling; Patricia Devaux; Roberto Cattaneo
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Early signal transduction in measles virus-infected lymphocytes is unaltered, but second messengers activate virus replication.

Authors:  R Vainionpää; T Hyypiä; K E Akerman
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.